# Coronary Artery Calcium AI Tool

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/coronary-artery-calcium-ai-tool
Canonical HTML page: https://getfinancebrief.com/entity/coronary-artery-calcium-ai-tool

## Timeline

- **2026-09-09**: Q2 earnings call — Nano-X management presents second-quarter results, emphasizing cost cuts, distributor expansion, and early imaging network economics.
- **2026-06-30**: Second quarter ends — Nano-X's fiscal second quarter closes with revenue of $4.2 million and a $40.7 million impairment charge.
- **2026-04-01**: Medicare CAC analysis code effective — A new Medicare code covering algorithmic analysis of coronary artery calcium takes effect, opening reimbursement for Nano-X's cardiac AI tool.
- **2025-11-19**: Nano-X acquires Nanox Health IT — Nano-X Imaging completes the acquisition of Nanox Health IT, later consolidated into Q2 2026 results.

## Recent coverage (1 stories)

### Nano-X Revenue Up 37% to $4.2M, But Cash Halved and $40.7M Impairment Hits
2026-09-13 17:33:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Nano-X grew Q2 revenue 37% to $4.2 million but took a $40.7 million impairment and saw cash shrink by nearly half in six months. Management is cutting costs and leaning on distributors, but the cash runway is the central market risk.
Full story: https://getfinancebrief.com/story/nano-x-q2-2026-cash-burn-impairment

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.